-
Register Now
-
Please register for this event HERE.
Special Services
For any special accomodations, please contact p3@remedica.com.
University of Kentucky is an Equal Opportunity Employer

Accreditation Information
In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Remedica Medical Education and Publishing, Ltd.. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME
This live activity is designated for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Other
UK Healthcare CECentral certifies this activity for 1.50 hours of participation.
Needs Statement
P³ is an innovative, global educational program designed to improve the management of patients with advanced prostate cancer. Content for the workshop is based around a series of case studies exploring current management challenges, all with a view to help guide optimal benefit–risk-based treatment sequencing and individualize treatment decisions for our patients.
Objectives
Upon completion of this educational activity, participants will be able to:
1. Demonstrate an understanding of clinical practice guidelines for the treatment of patients with advanced prostate cancer
2. Interpret the latest data supporting the use of new agents for advanced prostate cancer
3. Evaluate the differences among new therapies to help guide optimal benefit–risk-based treatment sequencing during the disease course
Target Audience
P3 workshops are for physicians and other healthcare professionals who treat patients with advanced prostate cancer and want to optimize the management of these patients.